CN115227863A - 一种搭载噬菌体的复合水凝胶及其制备方法 - Google Patents
一种搭载噬菌体的复合水凝胶及其制备方法 Download PDFInfo
- Publication number
- CN115227863A CN115227863A CN202210773841.0A CN202210773841A CN115227863A CN 115227863 A CN115227863 A CN 115227863A CN 202210773841 A CN202210773841 A CN 202210773841A CN 115227863 A CN115227863 A CN 115227863A
- Authority
- CN
- China
- Prior art keywords
- phage
- composite hydrogel
- solution
- silk fibroin
- bacteriophage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 66
- 239000002131 composite material Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 206010052428 Wound Diseases 0.000 claims abstract description 38
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 38
- 108010022355 Fibroins Proteins 0.000 claims abstract description 33
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 28
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims abstract description 12
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 6
- 241001524679 Escherichia virus M13 Species 0.000 claims description 23
- 241001515965 unidentified phage Species 0.000 claims description 22
- 239000012535 impurity Substances 0.000 claims description 12
- 241000701867 Enterobacteria phage T7 Species 0.000 claims description 9
- 238000004132 cross linking Methods 0.000 claims description 8
- 241000255789 Bombyx mori Species 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000013329 compounding Methods 0.000 claims description 2
- 230000002101 lytic effect Effects 0.000 claims description 2
- 230000006870 function Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 238000010166 immunofluorescence Methods 0.000 description 16
- 230000033115 angiogenesis Effects 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
Abstract
本发明公开了一种搭载噬菌体的复合水凝胶及其制备方法。复合水凝胶主要由丝素蛋白结合噬菌体形成;通过京尼平交联丝素蛋白和两种噬菌体形成搭载噬菌体的复合水凝胶材料。本发明的复合水凝胶可搭载不同功能化的噬菌体从而呈现出不同的功能,并且复合水凝胶可以直接涂布在伤口表面,为糖尿病伤口等创伤的治疗提供了新的方法和材料。
Description
技术领域
本发明属于生物医用材料领域的一种复合水凝胶及其制备方法,尤其是涉及了一种用于糖尿病伤口修复的搭载噬菌体的复合水凝胶及其制备方法。
背景技术
糖尿病伤口是糖尿病(Diabetes Mellitus,DM)长期病程中常见而且复杂的并发症之一。14-24%的患有糖尿病伤口的患者都会被截肢,这些患者在五年内的死亡率超过50%。并且糖尿病伤口容易引发感染。多种内在病理因素(血管流动不畅、神经病变和免疫功能受损)和外在因素(微生物感染和压力感知异常)可能是导致糖尿病伤口愈合不良的主要原因。虽然糖尿病伤口愈合失败的具体机制尚不十分清楚,但阻碍糖尿病伤口正常愈合的一个潜在原因是伤口微环境缺乏血管网络导致血流不畅。此外,耐药细菌感染被认为是造成糖尿病伤口持久而顽固的另一个重要因素。然而,在糖尿病伤口治疗中同时实现血管生成和抗菌仍然具有挑战性。
现有的丝素蛋白水凝胶可以采用物理交联和化学交联制备,功能单一,虽然生物相容性良好但是不能刺激血管生成和实现有效杀菌。
发明内容
针对于糖尿病伤口难以修复的问题,本发明设计了一种创伤敷料,该敷料以丝素蛋白作为基质材料,以噬菌体作为基质材料和功能因子,采用化学交联的方式制备出搭载噬菌体的复合水凝胶。
本发明制备的搭载噬菌体的复合水凝胶可以用于糖尿病伤口的修复,能够有效促进伤口组织血管生成、成纤维细胞增殖和浸润、抗菌、诱导巨噬细胞转化和止血。
本发明的技术方案是:
一、一种搭载噬菌体的复合水凝胶:
所述的复合水凝胶主要由丝素蛋白结合噬菌体制备形成。
所述的噬菌体包含裂解性噬菌体、温和型噬菌体、野生型噬菌体以及基因工程化噬菌体等噬菌体。
所述的噬菌体包括两种噬菌体,分别为M13噬菌体和T7噬菌体。
所述的复合水凝胶在制备治疗糖尿病伤口药物中应用。
二、一种搭载噬菌体的复合水凝胶的制备方法:
S1、使用京尼平交联M13噬菌体获得活化的M13噬菌体溶液;
S2、在活化的M13噬菌体上复合交联丝素蛋白并加入T7噬菌体制备复合水凝胶。
所述的步骤S1具体是将京尼平溶解在M13噬菌体溶液中搅拌制备出活化的M13噬菌体溶液。
所述的步骤S2具体为:
S21、将蚕茧茧壳剪碎、脱胶、洗涤、干燥、溶解、透析和除杂后制备成2w/v%的丝素蛋白溶液;
S22、将S21制备的丝素蛋白溶液加入到活化的M13噬菌体溶液中,搅拌至粘稠状态;
S23、将T7噬菌体溶液加入到粘稠溶液中并固化形成复合水凝胶。
所述的M13噬菌体溶液是通过侵染细菌、培养、离心、沉降、溶解和除杂后制备获得。
所述的T7噬菌体溶液是通过侵染细菌、培养、离心、沉降、溶解和除杂后制备获得。
所述的复合水凝胶为蓝色,孔洞大小约为10-300μm,吸水率约为1000%-3000%,M13噬菌体搭载量为1×102PFU/g–1×1011PFU/g,T7噬菌体搭载量为1×102PFU/g–1×1010PFU/g。
本发明在丝素蛋白搭载噬菌体复合制备过程中加入了京尼平,利用丝素蛋白和M13噬菌体游离的氨基以化学交联的方式成功将丝素蛋白和M13噬菌体复合,并加入了游离的T7噬菌体,制备出复合水凝胶,实现了噬菌体的搭载,使丝素水凝胶被噬菌体高度功能化,对后期体内治疗糖尿病伤口带来更佳的修复效果。
本发明所述的复合水凝胶通过京尼平与氨基的反应将M13噬菌体和丝素蛋白交联在一起,然后将游离的T7噬菌体加入到反应体系中形成。
本发明所述的搭载噬菌体的复合水凝胶表面上搭载的噬菌体可以增加创伤中成纤维细胞的迁移和胶原蛋白的分泌。
本发明所述的复合水凝胶可以直接涂覆在伤口表面,在伤口部位强烈诱导血管生成,水凝胶中的T7噬菌体可以有效杀灭耐药菌。
所述复合水凝胶以噬菌体和丝素蛋白为基质材料,形成蓝色的,孔洞大小约为10-300μm,吸水率约为1000%-3000%的水凝胶,通过京尼平与噬菌体和丝素蛋白上氨基的反应形成搭载噬菌体的复合水凝胶。
本发明所述的复合水凝胶可以搭载不同功能化的噬菌体从而呈现出不同的功能,并且复合水凝胶可以直接覆盖在病灶位置,为糖尿病伤口等诸多疾病的治疗提供了新的方法和材料。
与现有技术相比,本发明具有以下突出特点:
1)优良的生物相容性:丝素蛋白作为一种天然蛋白分子,对人体不会产生毒性,不会引起人体免疫反应;噬菌体是存在于人体的细菌病毒,不会对人体产生毒性;
2)促进伤口组织修复:搭载噬菌体的复合水凝胶在伤口部位诱导成纤维细胞的迁移和胶原蛋白的沉积,并且噬菌体可以强烈诱导血管网络的生成,为伤口组织的再生提供氧气和营养物质;水凝胶为细胞浸润和增殖提供物理支撑;
3)多功能性:噬菌体可以通过基因工程将功能性的多肽展示在噬菌体表面形成功能化的噬菌体,搭载不同功能化的噬菌体可以使复合水凝胶具备多种不同的功能;
5)成本低廉,环保无污染。
本发明的复合水凝胶可搭载不同功能化的噬菌体从而呈现出不同的功能,并且复合水凝胶可以直接涂布在伤口表面,为糖尿病伤口等创伤的治疗提供了新的方法和材料。
附图说明
图1为对比例1中水凝胶在第4天对糖尿病伤口部位血管生成的促进效果免疫荧光图(a)和噬菌体的免疫荧光图(b)。
图2为对比例2中水凝胶在第4天对糖尿病伤口部位血管生成的促进效果免疫荧光图(a)和噬菌体的免疫荧光图(b)。
图3为对比例3中水凝胶在第4天对糖尿病伤口部位血管生成的促进效果免疫荧光图(a)和噬菌体的免疫荧光图(b)。
图4为实施例1中水凝胶在第4天对糖尿病伤口部位血管生成的促进效果免疫荧光图(a)和噬菌体的免疫荧光图(b)。
具体实施方式
下面结合实施例对本发明作进一步的阐述,以下实施例仅为本发明的优选实施例,并不限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化,凡在本发明的精神和原则之内,所作的的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
本发明的实施例具体如下:
对比例1
1)将蚕茧茧壳剪碎、脱胶、洗涤、干燥、溶解、透析和除杂后制备成2%(w/v)的丝素蛋白溶液;
2)将京尼平(20mg/mL)溶解在1)中的丝素蛋白溶液(1mL,2%w/w)中,并在37℃下以150rpm反应2h形成粘稠液体;
3)将2)的粘稠液体静置30min以形成无噬菌体的丝素水凝胶。
所得的水凝胶的组成成分是丝素蛋白,所述的水凝胶的吸水率为2553%,孔洞大小约为50-300μm,噬菌体含量为0PFU/g。
本对比例的水凝胶在第4天对糖尿病伤口部位血管生成的促进效果免疫荧光如图1的(a)所示,噬菌体的免疫荧光如图1的(b)所示。
对比例2
1)通过细菌侵染、培养、离心、沉降、溶解和除杂后制备出1×1012PFU/mL的M13噬菌体溶液;
2)将京尼平(20mg/mL)溶解在1)中1mL的M13噬菌体溶液(1×1012PFU/mL)中,在37℃,150rpm反应3h;
3)将蚕茧茧壳剪碎、脱胶、洗涤、干燥、溶解、透析和除杂后制备成的丝素蛋白溶液;
4)在2)中的反应液中加入3)中的1mL丝素蛋白溶液(2w/v%),与M13噬菌体在37℃下以150rpm交联2h;
5)将4)中反应后的溶液静置形成只含有M13噬菌体的复合水凝胶。
所得的水凝胶的组成成分是丝素蛋白和M13噬菌体,所述的水凝胶的吸水率为2425%,孔洞大小约为10-300μm,M13噬菌体含量为9.83×1010PFU/g,T7噬菌体含量为0PFU/g。
本对比例的水凝胶在第4天对糖尿病伤口部位血管生成的促进效果免疫荧光如图2的(a)所示,噬菌体的免疫荧光如图2的(b)所示。
对比例3
1)通过细菌侵染、培养、离心、沉降、溶解和除杂后制备出1×1010PFU/mL的T7噬菌体溶液;
2)将蚕茧茧壳剪碎、脱胶、洗涤、干燥、溶解、透析和除杂后制备成的丝素蛋白溶液;
3)将京尼平(20mg/mL)溶解在2)中的丝素蛋白溶液(1mL,2%w/w)中,并在37℃下以150rpm反应2h形成粘稠液体;
4)将1)中的T7噬菌体以1×106PFU的含量加入到3)中的粘稠液体中,搅拌均匀;
5)将4)的粘稠液体静置30min以形成只含有T7噬菌体的复合水凝胶。
所得的水凝胶的组成成分是丝素蛋白和T7噬菌体,所述的水凝胶的吸水率为2678%,孔洞大小约为50-300μm,M13噬菌体含量为0PFU/g,T7噬菌体含量为1×106PFU/g。
本对比例的水凝胶在第4天对糖尿病伤口部位血管生成的促进效果免疫荧光如图3的(a)所示,噬菌体的免疫荧光如图3的(b)所示。
实施例1
1)通过细菌侵染、培养、离心、沉降、溶解和除杂后制备出1×1012PFU/mL的M13噬菌体溶液;
2)将京尼平(20mg/mL)溶解在1)中1mL的M13噬菌体溶液(1×1012PFU/mL)中,在37℃,150rpm反应3h;
3)将蚕茧茧壳剪碎、脱胶、洗涤、干燥、溶解、透析和除杂后制备成的丝素蛋白溶液;
4)在2)中的反应液中加入3)中的1mL丝素蛋白溶液(2w/v%),与M13噬菌体在37℃下以150rpm交联2h形成粘稠液体;
5)通过细菌侵染、培养、离心、沉降、溶解和除杂后制备出1×1010PFU/mL的T7噬菌体溶液;
6)将5)中的T7噬菌体以2×106PFU的含量加入到4)中的粘稠液体中,搅拌均匀;
7)将6)的粘稠液体静置30min以形成含有M13噬菌体和T7噬菌体的复合水凝胶。
所得的水凝胶的组成成分是丝素蛋白、M13噬菌体和T7噬菌体,所述的水凝胶的吸水率为2986%,孔洞大小约为10-300μm,M13噬菌体含量为9.83×1010PFU/g,T7噬菌体含量为1×106PFU/g。
本实施例的水凝胶在第4天对糖尿病伤口部位血管生成的促进效果免疫荧光如图4的(a)所示,噬菌体的免疫荧光如图4的(b)所示。
如图1-图4所示,根据本发明研究发现,将搭载噬菌体的复合水凝胶覆盖在糖尿病伤口上后,在植入后第4天,相比于没有搭载M13噬菌体的对比例1和对比例3,搭载M13噬菌体的实施例1能够在4天内明显刺激伤口部位的血管生成。在第4天,相比于没有搭载T7噬菌体的对比例1和对比例2,搭载T7噬菌体的实施例1能够在4天内彻底清除伤口感染的细菌并且T7噬菌体能够明显增殖。结果表明搭载M13噬菌体和T7噬菌体的复合水凝胶能够显著刺激糖尿病伤口部位生成血管和细菌清除。
Claims (7)
1.一种搭载噬菌体的复合水凝胶,其特征在于:
所述的复合水凝胶主要由丝素蛋白结合噬菌体制备形成。
2.根据权利要求1所述的一种搭载噬菌体的复合水凝胶,其特征在于:
所述的噬菌体包含裂解性噬菌体、温和型噬菌体、野生型噬菌体以及基因工程化噬菌体等噬菌体。
3.根据权利要求1所述的一种搭载噬菌体的复合水凝胶,其特征在于:
所述的噬菌体包括两种噬菌体,分别为M13噬菌体和T7噬菌体。
4.权利要求1-3任一所述复合水凝胶的应用,其特征在于:
所述的复合水凝胶在制备治疗糖尿病伤口药物中的应用。
5.权利要求1-3任一所述复合水凝胶的制备方法,其特征在于:
S1、使用京尼平交联M13噬菌体获得活化的M13噬菌体溶液;
S2、在活化的M13噬菌体上复合交联丝素蛋白并加入T7噬菌体制备复合水凝胶。
6.根据权利要求5所述的复合水凝胶的制备方法,其特征在于:
所述的步骤S1具体是将京尼平溶解在M13噬菌体溶液中搅拌制备出活化的M13噬菌体溶液。
7.根据权利要求5所述的复合水凝胶的制备方法,其特征在于:
所述的步骤S2具体为:
S21、将蚕茧茧壳剪碎、脱胶、洗涤、干燥、溶解、透析和除杂后制备成2w/v%的丝素蛋白溶液;
S22、将S21制备的丝素蛋白溶液加入到活化的M13噬菌体溶液中,搅拌至粘稠状态;
S23、将T7噬菌体溶液加入到粘稠溶液中并固化形成复合水凝胶。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210773841.0A CN115227863A (zh) | 2022-07-01 | 2022-07-01 | 一种搭载噬菌体的复合水凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210773841.0A CN115227863A (zh) | 2022-07-01 | 2022-07-01 | 一种搭载噬菌体的复合水凝胶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115227863A true CN115227863A (zh) | 2022-10-25 |
Family
ID=83670864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210773841.0A Pending CN115227863A (zh) | 2022-07-01 | 2022-07-01 | 一种搭载噬菌体的复合水凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115227863A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103796683A (zh) * | 2011-04-21 | 2014-05-14 | 塔夫茨大学信托人 | 用于活性试剂稳定化的方法和组合物 |
CN110305202A (zh) * | 2019-07-03 | 2019-10-08 | 浙江大学 | 一种改善丝素蛋白生物矿化能力的方法 |
-
2022
- 2022-07-01 CN CN202210773841.0A patent/CN115227863A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103796683A (zh) * | 2011-04-21 | 2014-05-14 | 塔夫茨大学信托人 | 用于活性试剂稳定化的方法和组合物 |
CN110305202A (zh) * | 2019-07-03 | 2019-10-08 | 浙江大学 | 一种改善丝素蛋白生物矿化能力的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4667486B2 (ja) | 水溶性エラスチンの架橋剤 | |
CN110354295B (zh) | 一种光热转换材料及其制备方法 | |
CN112300420B (zh) | 一种可注射抗菌互穿双网络水凝胶及其制备方法和应用 | |
CN104857569A (zh) | 一种丝素与氧化石墨烯复合支架材料的制备方法 | |
Albu et al. | Collagen-based drug delivery systems for tissue engineering | |
CN112480434B (zh) | 一种铜离子抗菌水凝胶及制备方法和应用 | |
CN113509590B (zh) | 外泌体联合透明质酸的伤口敷料及其制备方法和应用 | |
CN111821514B (zh) | 一种丝素丝胶蛋白复合膜及其制备方法 | |
CN114404648A (zh) | 促进糖尿病创面修复可降解抗菌止血水凝胶的制备方法 | |
CN106215239B (zh) | 一种交联抗菌型脱细胞基质材料的制备方法 | |
WO2022116359A1 (zh) | 一种负载骨形成蛋白的水凝胶、制备方法及应用 | |
CN110507842B (zh) | 一种细菌纤维素/透明质酸/ε-聚赖氨酸功能型敷料及其制备方法 | |
Liu et al. | Biomaterials for promoting wound healing in diabetes | |
Ramzan et al. | Zinc oxide loaded chitosan-elastin-sodium alginate nanocomposite gel using freeze gelation for enhanced adipose stem cell proliferation and antibacterial properties | |
Vijayan et al. | Lanthanum oxide nanoparticle-collagen bio matrix induced endothelial cell activation for sustained angiogenic response for biomaterial integration | |
Bakhtiar et al. | Fabrication and characterization of a novel injectable human amniotic membrane hydrogel for dentin-pulp complex regeneration | |
CN108478852A (zh) | 一种药学制品、用于负载医药制品的载体、水凝胶及其方法 | |
CN115227863A (zh) | 一种搭载噬菌体的复合水凝胶及其制备方法 | |
CN115850733B (zh) | 一种可注射用纳米粘土水凝胶及其制备方法和应用 | |
CN111001041A (zh) | 一种抗炎抗菌复合皮肤支架材料及制备方法 | |
CN110711264B (zh) | 复合材料、医用粘合剂及其制备方法和应用 | |
CN107441561B (zh) | 一种主动引导组织再生修复的仿生胶原基材料的制备方法 | |
CN115181226A (zh) | 一种小分子丝素蛋白基水凝胶及其制备方法和应用 | |
CN105727358B (zh) | 载药生物高分子复合纳米纤维膜及其制备方法 | |
Magagula et al. | Biopolymer-based biodegradable biomaterials for in vivo and in vitro biomedical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221025 |
|
RJ01 | Rejection of invention patent application after publication |